JP2015511632A - メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 - Google Patents

メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 Download PDF

Info

Publication number
JP2015511632A
JP2015511632A JP2015502543A JP2015502543A JP2015511632A JP 2015511632 A JP2015511632 A JP 2015511632A JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015511632 A JP2015511632 A JP 2015511632A
Authority
JP
Japan
Prior art keywords
tak
melanoma
use according
treatment
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511632A5 (enExample
Inventor
健雄 有田
健雄 有田
俊太郎 土屋
俊太郎 土屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2015511632A publication Critical patent/JP2015511632A/ja
Publication of JP2015511632A5 publication Critical patent/JP2015511632A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015502543A 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 Pending JP2015511632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618006P 2012-03-30 2012-03-30
US61/618,006 2012-03-30
PCT/IB2013/052556 WO2013144923A1 (en) 2012-03-30 2013-03-29 Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma

Publications (2)

Publication Number Publication Date
JP2015511632A true JP2015511632A (ja) 2015-04-20
JP2015511632A5 JP2015511632A5 (enExample) 2016-06-02

Family

ID=48326371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502543A Pending JP2015511632A (ja) 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与

Country Status (6)

Country Link
US (1) US20150126533A1 (enExample)
EP (1) EP2830664A1 (enExample)
JP (1) JP2015511632A (enExample)
CN (1) CN104428001A (enExample)
CA (1) CA2868954A1 (enExample)
WO (1) WO2013144923A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017511313A (ja) * 2014-03-26 2017-04-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 汎ｒａｆキナーゼ阻害剤の薬学的製剤、その調製プロセス、及び使用方法
JP2023548600A (ja) * 2020-11-06 2023-11-17 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド 低グレード神経膠腫を処置するためのｒａｆインヒビター

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3068393T (pt) 2013-11-11 2022-06-14 Amgen Inc Terapia de combinação, incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cancros
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
US20190117652A1 (en) * 2014-12-23 2019-04-25 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
CN115023230A (zh) * 2019-11-27 2022-09-06 首日生物制药公司 泛raf激酶抑制剂的固体分散体
CN117042772A (zh) * 2020-11-06 2023-11-10 首日生物制药公司 用于治疗低级别胶质瘤的raf抑制剂
CN117177754A (zh) * 2021-02-19 2023-12-05 首日生物制药公司 Raf抑制剂和mek抑制剂的组合
MX2023009642A (es) * 2021-02-19 2023-10-16 Day One Biopharmaceuticals Inc Combinacion de inhibidor de raf e inhibidor de mek.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
JP2010514680A (ja) * 2006-12-20 2010-05-06 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2010064722A1 (en) * 2008-12-02 2010-06-10 Takeda Pharmaceutical Company Limited Benzothiazole derivatives as anticancer agents
JP2010532380A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な化合物
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514680A (ja) * 2006-12-20 2010-05-06 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
JP2010532380A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な化合物
WO2010064722A1 (en) * 2008-12-02 2010-06-10 Takeda Pharmaceutical Company Limited Benzothiazole derivatives as anticancer agents
WO2011047238A1 (en) * 2009-10-16 2011-04-21 Glaxosmithkline Llc Combination

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017511313A (ja) * 2014-03-26 2017-04-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 汎ｒａｆキナーゼ阻害剤の薬学的製剤、その調製プロセス、及び使用方法
JP2023548600A (ja) * 2020-11-06 2023-11-17 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド 低グレード神経膠腫を処置するためのｒａｆインヒビター

Also Published As

Publication number Publication date
WO2013144923A1 (en) 2013-10-03
CN104428001A (zh) 2015-03-18
US20150126533A1 (en) 2015-05-07
CA2868954A1 (en) 2013-10-03
EP2830664A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
JP2015511632A (ja) メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
CN104245699B (zh) Nedd8‑活化酶抑制剂和低甲基化剂的投与
JP5345323B2 (ja) 癌を処置するための治療剤の組合せ
JP2002504511A (ja) 癌処置のためのエポチロンの使用
US20120059005A1 (en) Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) an antidiabetic compound for use in the treatment of proliferative diseases
TW201817425A (zh) 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法
JP7120691B2 (ja) 非アルコール性脂肪肝炎の予防または治療用の薬学組成物
JP7734742B2 (ja) 癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用
TW202038932A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
TW202045180A (zh) 治療纖維化之方法
JP2019112461A (ja) Ｎｅｄｄ８活性化酵素阻害剤及び化学療法剤の投与
TR201806682T4 (tr) Farmasötik kombinasyonlar.
JP2025508548A (ja) 淡明細胞型腎細胞癌の治療
JP7762224B2 (ja) 線維化症の予防または治療用薬学的組成物
US20240075041A1 (en) Treatment of eosinophilic disorders with avapritinib
AU2017342240A1 (en) Methods for treating ocular disease using inhibitors of CSF-1R
JP2008509992A (ja) チオウレア誘導体を含有する掻痒性もしくは刺激性皮膚疾患の予防または治療用組成物
KR20220043047A (ko) 스핑고신-1-인산 수용체 효능제의 용도
CN115427033A (zh) 用于治疗选自脓毒症、脓毒症休克、急性呼吸窘迫综合征(ards)或多器官功能障碍综合征(mods)的疾病的nk-1受体拮抗剂
TW201315471A (zh) 使用ＰＩ３Ｋβ抑制劑及包括ＭＥＫ及ＲＡＦ抑制劑之ＭＡＰＫ通道抑制劑之供治療癌症之組合物及方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170801